Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period.

De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S, Farley MM, Harrison LH, Lynfield R, Bennett NM, Baumbach J, Thomas A, Schaffner W, Beall B, Whitney C, Moore M.

Vaccine. 2012 Jun 8;30(27):4067-72. doi: 10.1016/j.vaccine.2012.04.017. Epub 2012 Apr 21.

PMID:
22525797
2.

Estimating pandemic vaccine effectiveness in two Italian regions using the screening method, 2009-2010.

Seyler T, Bella A, Puzelli S, Donatelli I, Rizzo C; screening method working group.

Vaccine. 2012 Jan 5;30(2):109-11. doi: 10.1016/j.vaccine.2011.11.013. Epub 2011 Nov 17.

PMID:
22100893
3.

National and state vaccination coverage among children aged 19-35 months--United States, 2010.

Centers for Disease Control and Prevention (CDC).

MMWR Morb Mortal Wkly Rep. 2011 Sep 2;60(34):1157-63.

4.

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine.

Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, Reingold A, Thomas A, Schaffner W, Craig AS, Smith PJ, Beall BW, Whitney CG, Moore MR; Active Bacterial Core Surveillance/Emerging Infections Program Network.

J Infect Dis. 2010 Jan 1;201(1):32-41. doi: 10.1086/648593.

PMID:
19947881
5.

Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age.

Lucero MG, Dulalia VE, Nillos LT, Williams G, Parreño RA, Nohynek H, Riley ID, Makela H.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD004977. doi: 10.1002/14651858.CD004977.pub2. Review.

PMID:
19821336
6.

Measles outbreak in South Africa, 2003-2005.

McMorrow ML, Gebremedhin G, van den Heever J, Kezaala R, Harris BN, Nandy R, Strebel P, Jack A, Cairns KL.

S Afr Med J. 2009 May;99(5):314-9.

PMID:
19588791
7.

PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007.

Carvalho Mda G, Pimenta FC, Gertz RE Jr, Joshi HH, Trujillo AA, Keys LE, Findley J, Moura IS, Park IH, Hollingshead SK, Pilishvili T, Whitney CG, Nahm MH, Beall BW; Active Bacterial Core Surveillance Team.

J Clin Microbiol. 2009 Mar;47(3):554-9. doi: 10.1128/JCM.01919-08. Epub 2008 Dec 30.

8.

Effect of vaccine shortages on timeliness of pneumococcal conjugate vaccination: results from the 2001-2005 National Immunization Survey.

Smith PJ, Nuorti JP, Singleton JA, Zhao Z, Wolter KM.

Pediatrics. 2007 Nov;120(5):e1165-73.

PMID:
17974712
9.

Pneumococcal conjugate vaccine for childhood immunization--WHO position paper.

[No authors listed]

Wkly Epidemiol Rec. 2007 Mar 23;82(12):93-104. English, French. No abstract available.

10.

Vaccine effectiveness estimates, 2004-2005 mumps outbreak, England.

Cohen C, White JM, Savage EJ, Glynn JR, Choi Y, Andrews N, Brown D, Ramsay ME.

Emerg Infect Dis. 2007 Jan;13(1):12-7.

11.

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study.

Whitney CG, Pilishvili T, Farley MM, Schaffner W, Craig AS, Lynfield R, Nyquist AC, Gershman KA, Vazquez M, Bennett NM, Reingold A, Thomas A, Glode MP, Zell ER, Jorgensen JH, Beall B, Schuchat A.

Lancet. 2006 Oct 28;368(9546):1495-502.

PMID:
17071283
12.

Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction.

Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME.

Lancet. 2004 Jul 24-30;364(9431):365-7.

PMID:
15276396
13.

Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method.

Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP.

J Infect Dis. 2003 Aug 15;188(4):481-5. Epub 2003 Jul 31.

PMID:
12898433
14.

Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine.

Whitney CG, Farley MM, Hadler J, Harrison LH, Bennett NM, Lynfield R, Reingold A, Cieslak PR, Pilishvili T, Jackson D, Facklam RR, Jorgensen JH, Schuchat A; Active Bacterial Core Surveillance of the Emerging Infections Program Network.

N Engl J Med. 2003 May 1;348(18):1737-46.

15.

Active bacterial core surveillance of the emerging infections program network.

Schuchat A, Hilger T, Zell E, Farley MM, Reingold A, Harrison L, Lefkowitz L, Danila R, Stefonek K, Barrett N, Morse D, Pinner R; Active Bacterial Core Surveillance Team of the Emerging Infections Program Network.

Emerg Infect Dis. 2001 Jan-Feb;7(1):92-9.

16.

Effectiveness of the pertussis vaccination program as determined by use of the screening method: United States, 1992-1994.

Guris D, Strebel PM, Tachdjian R, Bardenheier B, Wharton M, Hadler SC.

J Infect Dis. 1997 Aug;176(2):456-63.

PMID:
9237712
17.

Estimation of vaccine effectiveness using the screening method.

Farrington CP.

Int J Epidemiol. 1993 Aug;22(4):742-6.

PMID:
8225751
18.

Field evaluation of vaccine efficacy.

Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, Sirotkin B.

Bull World Health Organ. 1985;63(6):1055-68.

Supplemental Content

Support Center